FDA 483 - Fresenius Kabi USA LLC - May 18, 2020
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
An FDA inspection of Fresenius Kabi USA LLC in Melrose Park, IL, revealed significant deficiencies in quality control, equipment cleaning, aseptic processing, batch record documentation, and investigation procedures. The firm failed to adequately address particulate matter in Ketorolac, cross-contamination with Lidocaine in Dexmedetomidine, and lacked proper controls for sterile drug product manufacturing and hold times. These issues indicate a lack of adherence to current good manufacturing practices.
ID · c5c70f4e-1342-4dae-8ea8-fdfc56c82c6f